Neuphoria Therapeutics (NEUP) Interest & Investment Income (2023 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Interest & Investment Income of $186171.0 for Q1 2026, up 1361.2% year-over-year from $12741.0 in Q1 2025, and up 11.27% quarter-over-quarter from $167311.0 in Q4 2025.
Neuphoria Therapeutics (NEUP) Interest & Investment Income (2023 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Interest & Investment Income for 4 consecutive years, with $186171.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest & Investment Income rose 1361.2% year-over-year to $186171.0; the TTM figure through Mar 2026 stood at $582524.0 (up 450.7% YoY), while the FY2025 annual figure was $166498.0, down 24.35% from the prior year.
- Interest & Investment Income rose to $186171.0 in Q1 2026 per NEUP's latest filing, from $167311.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $186171.0 in Q1 2026 and bottomed at $12741.0 in Q1 2025.
- Historically, Interest & Investment Income has averaged $80188.5 across 4 years, with a median of $54716.0 in 2023.
- Annual changes were most pronounced in 2025 — Interest & Investment Income slumped 75.78% — and 2026, when it jumped 1361.2%.
- Neuphoria Therapeutics' Interest & Investment Income stood at $54716.0 in 2023, then sank by 44.05% to $30615.0 in 2024, then soared by 446.5% to $167311.0 in 2025, then grew by 11.27% to $186171.0 in 2026.
- Business Quant data shows NEUP's Interest & Investment Income at $186171.0 in Q1 2026, $167311.0 in Q4 2025, and $141996.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Neuphoria Therapeutics | 21.28 Mn | 1.84 Mn | - | 186,171.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 186,171.00 |
| Dec 31, 2025 | 167,311.00 |
| Sep 30, 2025 | 141,996.00 |
| Jun 30, 2025 | 87,046.00 |
| Mar 31, 2025 | 12,741.00 |
| Dec 31, 2024 | 30,615.00 |
| Sep 30, 2024 | 36,096.00 |
| Jun 30, 2024 | 26,327.00 |
| Mar 31, 2024 | 52,615.00 |
| Dec 31, 2023 | 54,716.00 |
| Sep 30, 2023 | 86,439.00 |